BASEL, Switzerland,
Oct. 29 /PRNewswire/ - Neuro-Biotech
Corporation (PINKSHEET: MRES) (OTCQB: MRES), pursuant to the
company's press release issued the 4th of october 2010, the following is a brief review and
explanation of the earlier statements concerning NeuroChAT also
known as Neuro-Bio Test #8 (formerly GACHA), which is able to
quantitatively measure the enzyme related to the synthesis of
acetylcholine, a neurotransmitter involved in cognitive disorders
like Alzheimer Disease.
Neuro-Biotech Corp. has developed a test unlike
no other. It enables the detection of Alzheimers Disease in its
earliest stages. The company intends to offer relevant tests for
people between 35 and 55 years of age to quickly focus on a proper
diagnosis. It is vitally important to be able to distinguish
between "Vascular cognitive disorders (VCD)," "Psychosis,"
"Senility," and "Dementia" (related to ageing). Thus by targeting
patients with appropriate therapeutic treatments, this allows
doctors to provide a better quality of care for their patients.
Neuro-Biotech Corp. shall encourage this beneficial
"doctor-patient" relationship at all times. Moreover, Medical
practitioners will be able to properly diagnose their patients and
start an early treatment with continued follow up in order to
report the initial symptoms and consequent damages.
It is important to note that when undergoing a
progressive clinical investigation involving the input and output
of the brain, the relationship between the brain, the adrenals and
the immune system has to be taken into account. In this
respect, quantitative measurement of the enzyme acetylcholine of
the main neurotransmitter involved in AD will present clinical
indications on the course of action to undertake.
It is well known that Alzheimer's Disease (AD)
is a progressive neurodegenerative disease that can begin as early
as the age of 30 (according to World Health Organization (WHO)) due
to medical incidents such as cerebral shock (concussion), cerebral
vascular accidents, drugs abuses, and severe depression. Last
year's World Alzheimer Report estimated that there are 35.6 million
people living with dementia worldwide in 2010, increasing to 65.7
million by 2030 and 115.4 million by 2050. Furthermore, this Report
mentions that the associated costs are presently evaluated at
604 Billion US dollars.
Neuro-Biotech Corp. will be able to prevent, and
defer the symptoms related to all the cognitive disorders and to
improve the quality of life through continuous follow-ups.
For more information, do not hesitate to contact
us by using the contact form on our corporate website at
neuro-biotechcorp.com. Your request will be transferred to the
appropriate persons and we will get back to you as soon as
possible.
Forward Looking Statements
This release contains statements that are made
pursuant to the Safe Harbor Provisions of the Private Securities
Litigation Act of 1995. Certain statements in this press release
may contain words such as "anticipates," "believes," "could,"
"expects," "intends," "may," "projects," "targets" and other
similar language that is considered forward-looking statements.
These forward-looking statements are subject to certain risks and
uncertainties and persons reading this release are cautioned that
such statements are only predictions, and that the Company's actual
future results or performance may be materially different. The
Company disclaims any intention or obligation to update or revise
forward-looking information, whether as a result of new
information, future events, or otherwise, could cause the company's
actual results to differ materially from those indicated in any
forward-looking statements.
CONTACT:
Neuro-Biotech Corp.
Dr Claude Poulin
41 61 500 05 16
info@neuro-agora.com
www.neuro-biotechcorp.com
SOURCE Neuro-Biotech Corp.
Copyright . 29 PR Newswire